UC Davis licenses novel compound that helps stem cells regenerate bone to treat bone diseases
Hybrid molecule LLP2A-Alendronate could have implications for osteonecrosis, fractures, osteoporosis and inflammatory arthritis. The University of California, Davis, is pleased to announce a licensing agreement with Regenerative Arthritis and Bone Medicine, Inc. (RABOME) for a class of drugs developed at UC Davis that hold potential for treating diseases associated with bone loss and inflammatory arthritis. […]

